KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.85

Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantation.

Nicolas Vallet, Sophie Le Grand, Louise Bondeelle, Bénédicte Hoareau, Aurélien Corneau, Delphine Bouteiller, Simon Tournier, Lucille Derivry, Armelle Bohineust, Marie Tourret, Delphine Gibert, Ethan Mayeur, Raphael Itzykson, Kim Pacchiardi, Brian Ingram, Stéphane Cassonnet, Patricia Lepage, Régis Peffault de Latour, Gérard Socié, Anne Bergeron, David Michonneau

Blood 140(23) 2500-2513

PMID35984904
PMCID-
DOI10.1182/blood.2022016926
发表日期2022-08-19
入排依据:While the study is an oncology randomized phase III trial with a drug intervention, it does not explicitly report formal time-to-event efficacy endpoints (e.g., OS, PFS, DFS) with standard metrics (Kaplan-Meier, HR) in the abstract. The focus is on mechanistic analysis of relapse association, not on primary efficacy results, so is_eligible is set to false.
摘要

摘要

Administration of azithromycin after allogeneic hematopoietic stem cell transplantation for hematologic malignancies has been associated with relapse in a randomized phase 3 controlled clinical trial. Studying 240 samples from patients randomized in this trial is a unique opportunity to better understand the mechanisms underlying relapse, the first cause of mortality after transplantation. We used multi-omics on patients' samples to decipher immune alterations associated with azithromycin intake and post-transplantation relapsed malignancies. Azithromycin was associated with a network of altered energy metabolism pathways and immune subsets, including T cells biased toward immunomodulatory and exhausted profiles. In vitro, azithromycin exposure inhibited T-cell cytotoxicity against tumor cells and impaired T-cell metabolism through glycolysis inhibition, down-regulation of mitochondrial genes, and up-regulation of immunomodulatory genes, notably SOCS1. These results highlight that azithromycin directly affects immune cells that favor relapse, which raises caution about long-term use of azithromycin treatment in patients at high risk of malignancies. The ALLOZITHRO trial was registered at www.clinicaltrials.gov as #NCT01959100.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。